Clinical trial
Kombucha in Overweight and Obese: Live Vs. Pasteurized Effects on Microbiota, Metabolism, and Liver Function
Recruiting now · Not applicable · 1 countries · Registry ID NCT06759324
What this study is about
Kombucha, a fermented beverage made from Camellia sinensis tea (black, oolong, or green) with sugar and a symbiotic culture of bacteria and yeast (SCOBY), has gained global attention for its potential health benefits. Factors like the type and amount of sugar substrate, fermentation time, and temperature significantly influence its organic compounds, total phenolics, vitamin content, and alcohol levels. In a previous study, kombucha's impact on glucose tolerance, insulin sensitivity, body composition, and liver function was tested in male prediabetic mice with diet-induced obesity. Daily supplementation (200 µL per mouse) improved glucose tolerance after nine days (equivalent to one year in humans) and reduced liver steatosis, despite no changes in body composition. Although kombucha has been associated with antioxidant, antimicrobial, probiotic, antidiabetic, and anticancer activities, strong scientific evidence in humans remains limited. Further clinical studies are needed to substantiate kombucha's health benefits in humans.
Basic eligibility
Full registry criteria
Treatments and study arms
Live kombucha (non filtered/ non pasteurized)
Participants receive a daily amount of 33 cl of live kombucha (non-pasteurized/ non-filtered) for 4 weeks (28 days).
Pasteurized kombucha (non filtered)
Participants receive a daily amount of 33 cl of kombucha (pasteurized drink) for 4 weeks (28 days).
Control (sparkling water)
Participants receive a daily amount of 33 cl of sparkling water for 4 weeks.
Primary outcomes
Analyze the changes in the relative abundance of the microbial species present, including taxonomic identification and diversity analysis, from baseline to the end of intervention, by next-generation sequencing (NGS).
Fasting glucose (mg/dl), from baseline to the end of intervention. Reduction is a better outcome.
Fasting insulin (μUI/mL), from baseline to the end of intervention. Reduction is a better outcome.
HOMA-IR values, from baseline to the end of intervention. Calculated from fasting glucose (mmol/L) X fasting insulin (mU/L) / 22.5). Less than 1.0 means insulin-sensitive, which is optimal. Above 1.9 indicates early insulin resistance. Above 2.9 indicates significant insulin resistance. Reduction is a better outcome.
Lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides), in mg/dL, from baseline to the end of intervention.
Study locations
2 locations were listed when this page was built. The first 40 are shown.